Hims & Hers Health Inc. (NYSE:HIMS)’s traded shares stood at 2.0 million during the last session. At the close of trading, the stock’s price was $8.61, to imply a decrease of -0.58% or -$0.05 in intraday trading. The HIMS share’s 52-week high remains $25.40, putting it -195.01% down since that peak but still an impressive 22.07% since price per share fell to its 52-week low of $6.71. The company has a valuation of $1.75B, with an average of 2.74 million shares in intraday trading volume over the past 10 days and average of 2.47 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Hims & Hers Health Inc. (HIMS), translating to a mean rating of 2.20. Of 4 analyst(s) looking at the stock, 0 analyst(s) give HIMS a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.06.
Hims & Hers Health Inc. (NYSE:HIMS) trade information
After registering a -0.58% downside in the last session, Hims & Hers Health Inc. (HIMS) has traded red over the past five days. The stock hit a weekly high of 9.35 this Thursday, 09/16/21, dropping -0.58% in its intraday price action. The 5-day price performance for the stock is -4.97%, and 24.60% over 30 days. With these gigs, the year-to-date price performance is -41.03%. Short interest in Hims & Hers Health Inc. (NYSE:HIMS) saw shorts transact 14.04 million shares and set a 9.35 days time to cover.
Analysts on Wall Street suggest a consensus price target of $11.75, implying an increase of 26.72% to the stock’s current value. The extremes give us $10.00 and $14.00 for target low and target high price respectively. As such, HIMS has been trading -62.6% off suggested target high and -16.14% from its likely low.
Hims & Hers Health Inc. (HIMS) estimates and forecasts
Looking at statistics comparing Hims & Hers Health Inc. share performance against respective industry, we note that the company has underperformed competitors. Hims & Hers Health Inc. (HIMS) shares are -46.22% down over the last 6 months, with its year-to-date growth rate lower than industry average at -178.26% against 6.10%. The rating firms project that company’s revenue will grow 70.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $70.53 million. Meanwhile, for the quarter ending Dec 2021, a total of 3 analyst(s) estimate revenue growth to $70.13 million.
Hims & Hers Health Inc. has its next earnings report out on May 17. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Hims & Hers Health Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Hims & Hers Health Inc. (NYSE:HIMS)’s Major holders
Hims & Hers Health Inc. insiders hold 20.45% of total outstanding shares, with institutional holders owning 58.14% of the shares at 73.09% float percentage. In total, 58.14% institutions holds shares in the company, led by Thrive Capital Management, LLC. As of Mar 30, 2021, the company held over 15.3 million shares (or 8.34% of shares), all amounting to roughly $202.47 million.
The next major institution holding the largest number of shares is Disruptive Technology Advisers, LLC with 9.19 million shares, or about 5.01% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $121.54 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund as the top two Mutual Funds with the largest holdings of the Hims & Hers Health Inc. (HIMS) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 2.32 million shares. This is just over 1.27% of the total shares, with a market valuation of $30.7 million. Data from the same date shows that the other fund manager holds a little less at 1.99 million, or 1.08% of the shares, all valued at about 26.27 million.